Klotho Therapeutics

Klotho Therapeutics, Inc., established in 2016, is a biotechnology firm centered on developing treatments based on the Klotho protein to address age-related diseases. The company was founded by James Plante and secured $10 million in a Series A financing round in November 2017, led by Thynk Capital, to advance the development of its proprietary Klotho protein variant, with an initial focus on kidney disease.

The company's core focus is the development of a modified, recombinant version of the human Klotho protein. This protein is fundamental to the company's therapeutic strategy, which aims to slow the progression of various age-related conditions. The firm holds patents for its modified Klotho proteins, which are designed for manufacturability using standard cell culture technology. The business model is geared towards minimizing traditional development risks to reduce the costs and time required to bring Klotho-based therapies to human trials. The initial market indication is acute kidney disease, a significant market with hundreds of thousands of fatalities annually in the U.S. alone. Beyond kidney disease, the company sees potential applications in treating cancer, cognitive decline, and other age-related disorders.

Klotho Therapeutics is developing a patent-pending, modified human Klotho protein that has the potential to impact the experience of aging. The natural Klotho hormone is associated with longevity and health, and lower levels are linked to disorders like cardiovascular disease, diabetes, and cognitive decline. The company's modified recombinant Klotho protein is designed to be manufacturable and has shown promise in animal studies for treating various cancers by suppressing tumor growth and inhibiting metastases. Evidence also supports that Klotho protein treatment can increase lifespan and enhance cognitive and memory function in animal models of Alzheimer's and premature aging.

Keywords: Klotho protein, biotechnology, age-related diseases, kidney disease, recombinant protein, cell culture technology, Series A funding, acute kidney disease, cancer treatment, cognitive decline, anti-aging, therapeutic development, human trials, modified proteins, venture capital, Thynk Capital, James Plante